Concerns about Anglo-Swedish drugs giant AstraZeneca's pipeline are likely to increase as the company abandoned work on its anti-depressant treatment TC-5214, which it developed in conjunction with US peer Targacept.
The two companies said top-line results from the remaining Phase 3 studies did not meet the primary endpoint and regulatory filing will not be pursued.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Can I inherit my partner's ISA? – little known tax break can boost your allowance by thousandsInheriting a partner’s ISA is fairly simple and comes with special advantages if you’re married or in a civil partnership – knowing what to do with it, however, isn’t always as straightforward
-
Can AI results boost Microsoft and Meta’s shares?Alphabet and Tesla’s stock saw contrasting movements after last week’s earnings. This week, Microsoft and Meta’s reports are followed by Amazon and Apple’s.
